Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials | Zendy

Antonio Abbate | Zendy; George F. Wohlford | Zendy; Marco Giuseppe Del Buono | Zendy; Juan Guido Chiabrando | Zendy; Roshanak Markley | Zendy; Jeremy Turlington | Zendy; Dinesh Kadariya | Zendy; Cory R. Trankle | Zendy; Giuseppe BiondiZoccai | Zendy; Michael J. Lipinski | Zendy; Benjamín Van Tassell | Zendy

Open Access

Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials

Author(s) -

Antonio Abbate,

George F. Wohlford,

Marco Giuseppe Del Buono,

Juan Guido Chiabrando,

Roshanak Markley,

Jeremy Turlington,

Dinesh Kadariya,

Cory R. Trankle,

Giuseppe BiondiZoccai,

Michael J. Lipinski,

Benjamín Van Tassell

Publication year - 2021

Publication title -

european heart journal - cardiovascular pharmacotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.895

H-Index - 26

eISSN - 2055-6845

pISSN - 2055-6837

DOI - 10.1093/ehjcvp/pvab075

Subject(s) - anakinra , medicine , myocardial infarction , heart failure , placebo , incidence (geometry) , cardiology , randomized controlled trial , clinical endpoint , gastroenterology , pathology , disease , physics , alternative medicine , optics

ST-segment elevation myocardial infarction (STEMI) is associated with an intense acute inflammatory response and an increased risk of death and heart failure (HF). In this study, we sought to evaluate the effect of anakinra, a recombinant interleukin-1 receptor antagonist, on the incidence of HF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research